Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Hamstra

Showing results (81-90 of 130) with videos related to

Pageof 13
Sort By:
Radiation Oncology (London, England)|June 12, 2012
Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapyJeffrey Vainshtein, Eyad Abu-Isa, Karin B Olson, et al.
Cancer|August 16, 2012
The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancerMark Shilkrut, Gregory S Merrick, P William McLaughlin, et al.
Journal of Neuro-Oncology|June 28, 2005
Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic studyDaniel A Hamstra, Bradford A Moffat, Daniel E Hall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate markerDaniel E Hall, Bradford A Moffat, Jadranka Stojanovska, et al.
Cancer|July 4, 2013
Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomyWilliam Jackson, Daniel A Hamstra, Skyler Johnson, et al.
Urology|November 28, 2017
Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published DataLawrence I Karsh, Eric T Gross, Christopher M Pieczonka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade gliomaChristina Tsien, Craig J Galbán, Thomas L Chenevert, et al.
Brachytherapy|April 28, 2015
Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5Adam L Liss, Eyad I Abu-Isa, Maha S Jawad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2018
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202James J Dignam, Daniel A Hamstra, Herbert Lepor, et al.
Translational Oncology|August 25, 2009
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacyCraig J Galbán, Suresh K Mukherji, Thomas L Chenevert, et al.
Pageof 13

Showing results (81-90 of 130) with videos related to

Sort By:
Pageof 13
Radiation Oncology (London, England)|June 12, 2012
Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapyJeffrey Vainshtein, Eyad Abu-Isa, Karin B Olson, et al.
Cancer|August 16, 2012
The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancerMark Shilkrut, Gregory S Merrick, P William McLaughlin, et al.
Journal of Neuro-Oncology|June 28, 2005
Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic studyDaniel A Hamstra, Bradford A Moffat, Daniel E Hall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate markerDaniel E Hall, Bradford A Moffat, Jadranka Stojanovska, et al.
Cancer|July 4, 2013
Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomyWilliam Jackson, Daniel A Hamstra, Skyler Johnson, et al.
Urology|November 28, 2017
Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published DataLawrence I Karsh, Eric T Gross, Christopher M Pieczonka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade gliomaChristina Tsien, Craig J Galbán, Thomas L Chenevert, et al.
Brachytherapy|April 28, 2015
Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5Adam L Liss, Eyad I Abu-Isa, Maha S Jawad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2018
Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202James J Dignam, Daniel A Hamstra, Herbert Lepor, et al.
Translational Oncology|August 25, 2009
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacyCraig J Galbán, Suresh K Mukherji, Thomas L Chenevert, et al.
Pageof 13